Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
US-11141393-B2 · Oct 12, 2021 · US
Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
US11839631B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11839631-B2 |
| Application number | US-202017072430-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 16, 2020 |
| Priority date | Aug 1, 2012 |
| Publication date | Dec 12, 2023 |
| Grant date | Dec 12, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treatment pulmonary hypertension, comprising administering to a subject suffering from pulmonary hypertension (i) a first prostacyclin and (ii) mesenchymal stem cells (MSCs), wherein the MSCs have been contacted with a second prostacyclin prior to administration. 2. The method of claim 1 , wherein the first and second prostacyclin are the same prostacyclin. 3. The method of claim 1 , wherein the first or second prostacyclin is treprostinil. 4. The method of claim 1 , wherein the first prostacyclin and MSCs are co-administered. 5. The method of claim 1 , wherein the first prostacyclin is administered before the MSCs are administered. 6. The method of claim 1 , wherein the first prostacyclin is administered after the MSCs are administered. 7. The method of claim 1 , wherein the MSCs are contacted with the second prostacyclin ex vivo. 8. The method of claim 7 , wherein the MSCs are contacted with a growth factor ex vivo. 9. The method of claim 1 , wherein the MSCs are obtained from the subject. 10. The method of claim 1 , wherein the patient is suffering from pulmonary arterial hypertension.
Assignees
Inventors
Classifications
- A61K35/44Primary
Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells · CPC title
having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin · CPC title
from inanimate materials (carbon A61K33/44) · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Stem cells; Progenitor cells; Precursor cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11839631B2 cover?
- The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
- Who is the assignee on this patent?
- United Therapeutics Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K35/44. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).